The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Savushkina O.K.

Mental Health Research Centre

Boksha I.S.

Mental Health Research Centre;
Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of the Russian Federation

Omelchenko M.A.

Mental Health Research Centre

Tereshkina E.B.

Mental Health Research Centre

Prokhorova T.A.

Mental Health Research Centre

Vorobyeva E.A.

Mental Health Research Centre

Burbaeva G.Sh.

Mental Health Research Centre

Activity of enzymes of glutamate, energy and glutathione metabolism in the first juvenile depression with attenuated symptoms of schizophrenia

Authors:

Savushkina O.K., Boksha I.S., Omelchenko M.A., Tereshkina E.B., Prokhorova T.A., Vorobyeva E.A., Burbaeva G.Sh.

More about the authors

Read: 1708 times


To cite this article:

Savushkina OK, Boksha IS, Omelchenko MA, Tereshkina EB, Prokhorova TA, Vorobyeva EA, Burbaeva GSh. Activity of enzymes of glutamate, energy and glutathione metabolism in the first juvenile depression with attenuated symptoms of schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(8):136‑144. (In Russ.)
https://doi.org/10.17116/jnevro2022122081136

Recommended articles:

References:

  1. Carrión RE, Demmin D, Auther AM, et al. Duration of attenuated positive and negative symptoms in individuals at clinical high risk: Associations with risk of conversion to psychosis and functional outcome. J Psychiatr Res. 2016;81:95-101.  https://doi.org/10.1016/j.jpsychires.2016.06.021
  2. Chang WC, Strauss GP, Ahmed AO, et al. The Latent Structure of Negative Symptoms in Individuals With Attenuated Psychosis Syndrome and Early Psychosis: Support for the 5 Consensus Domains. Schizophr Bull. 2021;47(2):386-394.  https://doi.org/10.1093/schbul/sbaa129
  3. Neznanov NG, Kocjubinskij AP, Mazo GJe. Biopsiho-social’naja psihiatrija. Rukovodstvo dlja vrachej. M.: SIMK; 2020. (In Russ.).
  4. Woodberry KA, Shapiro DI, Bryant C, et al. Progress and Future Directions in Research on the Psychosis Prodrome: A Review for Clinicians. Harv Rev Psychiatry. 2016;24(2):87-103.  https://doi.org/10.1097/HRP.0000000000000109
  5. Kline ER, Seidman LJ, Cornblatt BA, et al. Depression and clinical high-risk states: Baseline presentation of depressed vs. non-depressed participants in the NAPLS-2 cohort. Schizophr Res. 2018;192:357-363.  https://doi.org/10.1016/j.schres.2017.05.032
  6. Albert U, Tomassi S, Maina G, et al. Prevalence of non-psychotic disorders in ultra-high risk individuals and transition to psychosis: A systematic review. Psychiatry Res. 2018;270:1-12.  https://doi.org/10.1016/j.psychres.2018.09.028
  7. Modinos G, Richter A, Egerton A, et al. Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes. Neuropsychopharmacology. 2021;46(8):1468-1474. https://doi.org/10.1038/s41386-021-01019-0
  8. Uno Y, Coyle JT. Glutamate hypothesis in schizophrenia. Psychiatry Clin Neurosci. 2019;73(5):204-215.  https://doi.org/10.1111/pcn.12823
  9. Moghaddam B, Krystal JH. Capturing the angel in «angel dust»: twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull. 2012;38(5):942-949.  https://doi.org/10.1093/schbul/sbs075
  10. Hu W, MacDonald ML, Elswick DE, et al. The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. Ann N Y Acad Sci. 2015;1338(1):38-57.  https://doi.org/10.1111/nyas.12547
  11. Burbaeva GSh, Boksha IS, Tereshkina EB, et al. Systemic neurochemical alterations in schizophrenic brain: glutamate metabolism in focus. Neurochem Res. 2007;32(9):1434-1444. https://doi.org/10.1007/s11064-007-9328-7
  12. Savushkina OK, Tereshkina EB, Prokhorova TA, et al. Platelet glutamate dehydrogenase activity and efficacy of antipsychotic therapy in patients with schizophrenia. J Med Biochem. 2020;39(1):54-59.  https://doi.org/10.2478/jomb-2019-0018
  13. Steullet P, Cabungcal JH, Monin A, et al. Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A «central hub» in schizophrenia pathophysiology? Schizophr Res. 2016;176(1):41-51.  https://doi.org/10.1016/j.schres.2014.06.021
  14. Conus P, Seidman LJ, Fournier M, et al. N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis. Schizophr Bull. 2018;44(2):317-327.  https://doi.org/10.1093/schbul/sbx093
  15. Giuliani FA, Escudero C, Casas S, et al. Allopregnanolone and puberty: modulatory effect on glutamate and GABA release and expression of 3α-hydroxysteroid oxidoreductase in the hypothalamus of female rats. Neuroscience. 2013;243:64-75.  https://doi.org/10.1016/j.neuroscience.2013.03.053
  16. Gawryluk JW, Wang JF, Andreazza AC, et al. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol. 2011;14(1):123-130.  https://doi.org/10.1017/S1461145710000805
  17. Raffa M, Mechri A, Othman LB, et al. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(7):1178-1183. https://doi.org/10.1016/j.pnpbp.2009.06.018
  18. Chowdari KV, Bamne MN, Nimgaonkar VL. Genetic association studies of antioxidant pathway genes and schizophrenia. Antioxid Redox Signal. 2011;15(7):2037-2045. https://doi.org/10.1089/ars.2010.3508
  19. Do KQ, Trabesinger AH, Kirsten-Krüger M, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci. 2000;12(10):3721-3728. https://doi.org/10.1046/j.1460-9568.2000.00229.x
  20. Prokhorova TA, Tereshkina EB, Savushkina OK, et al. The activity of enzymes of glutathione metabolism in blood cells of patients with a high risk of manifestation of endogenous psychoses and patients with the first psychotic episode. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2019;119(4):47-54. (In Russ.). https://doi.org/10.17116/jnevro201911904147
  21. Tereshkina EB, Savushkina OK, Boksha IS, et al. Glutathione reductase and glutathione-S-transferase in blood cells in schizophrenia and schizophrenia spectrum disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2019;119(2):61-65. (In Russ.). https://doi.org/10.17116/jnevro201911902161
  22. Holper L, Ben-Shachar D, Mann JJ. Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease. Neuropsychopharmacology. 2019;44(5):837-849.  https://doi.org/10.1038/s41386-018-0090-0
  23. Omelchenko MA. Clinical Features of Youth Depression with Attenuated Symptoms of the Schizophrenic Spectrum. Psikhiatriya. 2021;19(1):16-25. (In Russ.). https://doi.org/10.30629/2618-6667-2021-19-1-16-25
  24. Rumyantsev AO, Omelchenko MA, Kaleda VG. Attenuated psychotic symptoms in the structure of youth depression (clinical and psychopathological aspects). Rossyiskyi psikhiatricheskii zhurnal. 2018;1:61-70. (In Russ.).
  25. Fusar-Poli P, Cappucciati M, De Micheli et al. Diagnostic and Prognostic Significance of Brief Limited Intermittent Psychotic Symptoms (BLIPS) in Individuals at Ultra High Risk. Schizophr Bull. 2017;43(1):48-56.  https://doi.org/10.1093/schbul/sbw151
  26. Patel MX, Arista IA, Taylor M, et al. How to compare doses of different antipsychotics: a systematic review of methods. Schizophr Res. 2013;149(1-3):141-148.  https://doi.org/10.1016/j.schres.2013.06.030
  27. Burbaeva GS, Boksha IS, Turishcheva MS, et al. Platelet cytochrome c-oxidase activity in patients with acute schizophrenia in the course of their treatment with risperidone. Health. 2011;3(1):13-19.  https://doi.org/10.4236/health.2011.31003
  28. Smulevich AB, Klyushnik TP, Lobanova VM, Voronova EI. Negative and positive disorders of schizophrenia (issues of co-dependence, psychopathology and pathogenesis). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2020;120(6-2):13-22. (In Russ.). https://doi.org/10.17116/jnevro202012006213
  29. Onaolapo AY, Onaolapo OJ. Glutamate and depression: Reflecting a deepening knowledge of the gut and brain effects of a ubiquitous molecule. World J Psychiatry. 2021;11(7):297-315.  https://doi.org/10.5498/wjp.v11.i7.297
  30. Ben-Shachar D, Zuk R, Gazawi H, et al. Increased mitochondrial complex I activity in platelets of schizophrenic patients. Int J Neuropsychopharmacol. 1999;2(4):245-253.  https://doi.org/10.1017/S1461145799001649
  31. Dror N, Klein E, Karry R, et al. State-dependent alterations in mitochondrial complex I activity in platelets: a potential peripheral marker for schizophrenia. Mol Psychiatry. 2002;7(9):995-1001. https://doi.org/10.1038/sj.mp.4001116
  32. Wu A, Da Silva T, Jacobson M, et al. Validating mitochondrial electron transport chain content in individuals at clinical high risk for psychosis. Sci Rep. 2019;9(1):12695. https://doi.org/10.1038/s41598-019-49180-3

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.